Schikan Sells Big Stake in Pharvaris | Business and Finance News

Johannes Schikan, Pharvaris director, cashed in big—selling 37,600 shares for $1.3M after the stock soared nearly 97% in a year. This isn’t his first move this year; he’s offloaded 80K shares since March, with this being his largest single sale. Still holding over 315K shares, he’s clearly not exiting entirely. Pharvaris, a biopharma firm targeting rare diseases like hereditary angioedema, is betting everything on its late-stage drug deucrictibant—with no revenue and consistent losses, regulatory wins are make-or-break. The sale was pre-planned, not panic-driven, and fits a common pattern for insiders cashing in after big gains. July’s flat stock movement hints the market may already expect this. The real test? Whether deucrictibant delivers for patients—and turns the company’s losses into wins. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/32fda570f2cf145f